scPharmaceuticals Inc. (NASDAQ:SCPH) is AIGH Capital Management LLC’s 7th Largest Position

AIGH Capital Management LLC boosted its position in scPharmaceuticals Inc. (NASDAQ:SCPH) by 1.2% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 4,174,367 shares of the company’s stock after buying an additional 50,000 shares during the quarter. scPharmaceuticals accounts for approximately 4.6% of AIGH Capital Management LLC’s holdings, making the stock its 7th biggest holding. AIGH Capital Management LLC owned about 8.34% of scPharmaceuticals worth $14,777,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also modified their holdings of SCPH. BNP Paribas Financial Markets raised its position in shares of scPharmaceuticals by 116.9% during the 3rd quarter. BNP Paribas Financial Markets now owns 5,753 shares of the company’s stock valued at $26,000 after acquiring an additional 3,101 shares in the last quarter. Legato Capital Management LLC bought a new stake in scPharmaceuticals during the fourth quarter valued at $37,000. China Universal Asset Management Co. Ltd. acquired a new stake in shares of scPharmaceuticals during the fourth quarter worth $38,000. Virtu Financial LLC bought a new position in shares of scPharmaceuticals in the 3rd quarter worth about $46,000. Finally, The Manufacturers Life Insurance Company acquired a new position in shares of scPharmaceuticals in the 3rd quarter valued at about $57,000. 89.52% of the stock is owned by hedge funds and other institutional investors.

scPharmaceuticals Trading Down 8.6 %

Shares of SCPH stock opened at $2.78 on Friday. scPharmaceuticals Inc. has a 1 year low of $2.72 and a 1 year high of $5.65. The firm has a market capitalization of $139.79 million, a PE ratio of -1.46 and a beta of 0.40. The stock has a fifty day moving average of $3.23 and a two-hundred day moving average of $3.70. The company has a debt-to-equity ratio of 1.66, a quick ratio of 6.89 and a current ratio of 8.08.

scPharmaceuticals (NASDAQ:SCPH) last posted its quarterly earnings data on Wednesday, March 19th. The company reported ($0.35) earnings per share for the quarter, topping the consensus estimate of ($0.40) by $0.05. The business had revenue of $12.15 million during the quarter, compared to the consensus estimate of $12.08 million. scPharmaceuticals had a negative net margin of 264.60% and a negative return on equity of 244.93%. As a group, research analysts expect that scPharmaceuticals Inc. will post -1.53 EPS for the current year.

Analyst Ratings Changes

Several equities analysts have recently commented on the stock. Maxim Group lowered their price target on shares of scPharmaceuticals from $20.00 to $12.00 and set a “buy” rating for the company in a research report on Thursday, March 20th. HC Wainwright reissued a “buy” rating and set a $18.00 target price on shares of scPharmaceuticals in a research note on Thursday, March 20th.

scPharmaceuticals Company Profile

scPharmaceuticals Inc, a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. Its lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion due to fluid overload in adults with chronic heart failure and kidney disease, as well as consists of subcutaneous loop diuretic that delivers IV equivalent diuresis at home; and FUROSCIX On-Body Infusor, a drug-device combination product consisting of FUROSCIX.